PHARNEXT: Pharnext supports and participates in the 27th Days of the Francophone Society of the Peripheral Nerve (SFNP) in Paris – 03/06/2023 at 08:30

PARIS, France, March 6, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400BV89 – ALPHA)

(the “Company”), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, today announces its support for the organization and its participation in the 27

^e

Days of the Francophone Society of the Peripheral Nerve (SFNP) which will be held in Paris on March 10 and 11, 2023.

This medical education meeting is intended for hospital and community neurologists who care for patients with diseases of the peripheral nervous system and muscles, including in particular Charcot-Marie-Tooth disease type 1A (CMT1A), a disease in which Pharnext’s most advanced drug candidate, PXT3003, is in pivotal Phase III development. This meeting will propose a transversal approach to these pathologies, combining the clinical point of view and the latest scientific information in the field.

In order to strengthen its links with the medical community involved in the management of neuromuscular diseases such as CMT1A in France, Pharnext has decided to support and participate in the 27

^e

SFNP Days. The Pharnext team will hold a stand for the duration of the congress.

The SFNP Days will be held at the Salons de l’Aveyron, 17 Rue de l’Aubrac, in Paris 12. More information on this medical education event is available at

www.journees-sfnp.fr

About Pharnext

Pharnext is a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases that currently have no satisfactory therapeutic solution. Pharnext has a new drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited, rare and debilitating peripheral neuropathy. PXT3003 has orphan drug status in Europe and the United States. In 2018, PXT3003 completed a Phase III clinical study, the PLEO-CMT trial, with encouraging preliminary results. This trial was followed by an open-label extension study, the PLEO-CMT-FU trial, in which 120 patients are still currently continuing treatment with PXT3003. The long-term results suggest a sustained benefit, in terms of tolerance and efficacy, after a total clinical study period of 5 years. A pivotal international Phase III clinical study, the PREMIER trial, is ongoing, in which 387 patients with CMT1A have been enrolled. The first results of the PREMIER trial are expected in the fourth quarter of 2023. PXT3003 was discovered with the R&D approach of Pleotherapy™. Pharnext draws investors’ attention to the risk factors, particularly financial, detailed in its financial reports. More information on

www.pharnext.com

.

Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400BV89).

contacts

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com